Healthcare insurance company Molina Healthcare (NYSE: MOH) reported Q3 2026 results beating Wall Street’s revenue expectations, but sales fell by 3.4% year on year to $11.08 billion. Its non-GAAP profit of $0.89 per share was 12% above analysts’ consensus estimates.

Is now the time to buy MOH? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Molina Healthcare’s third quarter results reflected continued pressure from a challenging medical cost environment, with year-on-year declines in revenue and membership. Management pointed to operational execution on recent contracts and modest margin stability as key drivers, despite persistent utilization pressure in Medicaid and Medicare. CEO Joe Zubretsky described the quarter’s Medicaid pre-tax margin as a “trough” in a multi-year cycle, emphasizing that recent rate updates helped offset higher medical costs. Zubretsky added, “The imbalance between rates and trend appears to have stabilized, which supports our view that current Medicaid margins represent the trough in a multi-year cycle.”

Looking ahead, Molina Healthcare’s outlook is shaped by anticipated improvements in Medicaid rates, expected normalization of medical cost trends, and the phased implementation of new contracts. Management is focused on operational ramp-up of the Florida CMS contract and is cautious about the pace of membership attrition due to new work requirements and eligibility reverifications. CFO Mark Keim noted, “We are tracking in 2026 to a 6% same-store membership decline,” but expects most states to implement policies that limit disenrollment. Zubretsky reiterated confidence in Medicaid margin recovery, citing strengthening rate cycles and state recognition of rising acuity and cost trends.

Key insights from management’s remarks

Management attributed the quarter’s performance to stable but elevated medical cost trends, the initial impact of new high-acuity Medicaid contracts, and the ongoing effects of program integrity initiatives in Marketplace.

• Medicaid margin stability: Management reported that Medicaid margins held steady due to recent rate increases, which helped offset higher utilization and acuity in medical costs. They described this as the “trough” before expected improvement as rates catch up to trend.

• Florida CMS contract launch: The company began implementing its $6 billion Florida CMS contract, onboarding 115,000 high-acuity pediatric members. Management described the operational rollout as “nearly flawless,” but expects initial losses in Q4 before reaching break-even in the second year.

• Membership attrition trends: Molina saw a modest decline in overall membership, in line with expectations for a 6% full-year decrease due to Medicaid redeterminations and policy changes, which the company expects to continue gradually over the next several years.

• Marketplace business repositioning: The company continued to reduce its Marketplace footprint in response to persistent losses, focusing on states where it can maintain adequate risk adjustment and scale for 2027.

• Medicare duals performance: Management highlighted strong performance in the duals-focused Medicare segment, with competitive supplemental benefits and margin contribution, while signaling the exit of the underperforming MAPD product in 2027 as part of a shift toward higher-return segments.

Drivers of future performance

Molina Healthcare’s outlook for the coming quarters will be driven by Medicaid rate cycle improvements, continued cost trend normalization, and operational execution on new and existing contracts.

• Medicaid rate cycle acceleration: Management expects stronger Medicaid rate increases for 2027, citing known January 1st renewals averaging about 7%. States are beginning to incorporate more recent medical claims data and prospective adjustments for acuity shifts, which could support margin recovery in legacy Medicaid.

• Membership attrition and acuity risk: The company projects a 6% membership decline next year due to the rollout of federal work requirements and biannual eligibility verifications. Management believes most states will adopt policies to limit disenrollment, but acknowledges the risk of higher acuity among remaining members, which could elevate medical costs.

• Execution on new contracts: The operational and financial ramp-up of the Florida CMS contract and delayed implementation of large contracts in Georgia and Texas are expected to influence earnings trajectory. Management remains confident that eventual contract launches will bolster revenue and operating leverage, though legal proceedings could delay timing.

Catalysts in upcoming quarters

In the coming quarters, our analysts will focus on (1) the pace at which Medicaid margins recover as new rate cycles take effect, (2) the operational and financial ramp-up of the Florida CMS contract, and (3) the timing and outcome of legal proceedings affecting large contract implementations in Georgia and Texas. Trends in medical cost utilization and state-level policy changes regarding eligibility will also be key signals to monitor.

Molina Healthcare currently trades at $214.54, in line with $214.79 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Now could be the perfect time to invest in these stocks

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.